Market attractiveness remains robust, driven by expanding neuro‑oncology and radiosurgery volumes and rising reimbursement for image‑guided procedures. Competitive intensity is moderate; a handful of legacy vendors dominate, yet new entrants leverage cloud‑based platforms and AI‑assisted contouring to erode margins. The long‑term outlook is positive, with CAGR projected above 9% through 2032 as clinical guidelines increasingly mandate stereotactic precision. Innovation landscape is vibrant: AI‑driven treatment planning, real‑time adaptive workflows, and integration with multimodal imaging are accelerating product cycles. Demand–supply balance is currently tight—hospitals seek scalable solutions faster than manufacturers can certify and roll out next‑gen software, creating a modest backlog that supports pricing power. Key risk factors include regulatory delays, cybersecurity threats, and potential consolidation that could limit customer choice. Geographically, adoption is accelerating in Asia‑Pacific as reimbursement frameworks evolve, while North America remains the revenue anchor. Overall, the Stereotactic Planning Software market outlook suggests sustained growth for firms that invest in AI, regulatory expertise, and flexible deployment models.